These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22635217)

  • 1. Secondary prevention in thrombotic antiphospholipid syndrome.
    Pengo V; Denas G; Banzato A; Bison E; Bracco A; Facchinetti M; Hoxha A; Ruffatti A
    Lupus; 2012 Jun; 21(7):734-5. PubMed ID: 22635217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
    Cohen H; Machin SJ
    Lupus; 2010 Apr; 19(4):486-91. PubMed ID: 20353992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiphospholipid antibodies in critical illness.
    Dentali F; Crowther M
    Crit Care Med; 2010 Feb; 38(2 Suppl):S51-6. PubMed ID: 20083914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome.
    Les I; Ruiz-Irastorza G; Khamashta MA
    Semin Thromb Hemost; 2012 Jun; 38(4):339-47. PubMed ID: 22467528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
    Finazzi G; Marchioli R; Brancaccio V; Schinco P; Wisloff F; Musial J; Baudo F; Berrettini M; Testa S; D'Angelo A; Tognoni G; Barbui T
    J Thromb Haemost; 2005 May; 3(5):848-53. PubMed ID: 15869575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'.
    Pengo V; Ruiz-Irastorza G; Denas G; Andreoli L; Khamashta M; Tincani A
    Autoimmun Rev; 2012 Jun; 11(8):577-80. PubMed ID: 22036827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New oral anticoagulants in thrombotic antiphospholipid syndrome.
    Chighizola CB; Moia M; Meroni PL
    Lupus; 2014 Oct; 23(12):1279-82. PubMed ID: 25228726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis.
    Meroni PL; Moia M; Derksen RH; Tincani A; McIntyre JA; Arnout JM; Koike T; Piette JC; Khamashta MA; Shoenfeld Y
    Lupus; 2003; 12(7):504-7. PubMed ID: 12892388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of thrombosis in antiphospholipid syndrome.
    Lim W
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):707-713. PubMed ID: 27913550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis.
    Brunner HI; Chan WS; Ginsberg JS; Feldman BM
    J Rheumatol; 2002 Mar; 29(3):490-501. PubMed ID: 11908562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.
    Dager WE
    Ann Pharmacother; 2012 Jan; 46(1):79-88. PubMed ID: 22202495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of thrombophilia in deciding on the duration of anticoagulation.
    Bauer KA
    Semin Thromb Hemost; 2004 Dec; 30(6):633-7. PubMed ID: 15630669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of thrombosis in the antiphospholipid-antibody syndrome.
    Khamashta MA; Cuadrado MJ; Mujic F; Taub NA; Hunt BJ; Hughes GR
    N Engl J Med; 1995 Apr; 332(15):993-7. PubMed ID: 7885428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation for venous thromboembolism: what if they bleed?
    Palareti G
    Hamostaseologie; 2012; 32(1):40-4. PubMed ID: 22009202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome.
    Cohen H; Efthymiou M; Gates C; Isenberg D
    Semin Thromb Hemost; 2018 Jul; 44(5):427-438. PubMed ID: 28196381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid syndrome and anticoagulation quality: a clinical challenge.
    Pastori D; Parrotto S; Vicario T; Saliola M; Mezzaroma I; Violi F; Pignatelli P
    Atherosclerosis; 2016 Jan; 244():48-50. PubMed ID: 26584138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The management of thrombosis in the antiphospholipid antibody syndrome: insights from recent clinical trials and remaining unsolved issues].
    Wahl D; Perret-Guillaume C; Piette JC
    Rev Med Interne; 2008 Sep; 29(9):731-4. PubMed ID: 18584919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.
    Girón-González JA; García del Río E; Rodríguez C; Rodríguez-Martorell J; Serrano A
    J Rheumatol; 2004 Aug; 31(8):1560-7. PubMed ID: 15290736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.